Roughly a quarter of all biliary tract cancer patients carry a KRAS mutation, and almost none of them reach a clinical trial with a mechanism designed specifically to exploit that vulnerability. GENFIT’s Phase 1b data for GNS561, a PPT1-targeting autophagy inhibitor combined with the MEK inhibitor trametinib, arrives against that backdrop: 19 patients, four dose cohorts, zero dose-limiting toxicities, and approximately half achieving stable disease at the six-week landmark. One patient held stable disease through week 30. These are small numbers from a heavily pretreated population, but the signal has been consistent as enrollment grew, which matters more than any single responder in a disease where second- and third-line options remain scarce.
The mechanistic logic is worth taking seriously. GNS561 disrupts lysosomal function and blocks late-stage autophagy, a survival pathway that cancer cells upregulate precisely when MAPK signaling is suppressed by a MEK inhibitor. The combination is designed to cut off both escape routes simultaneously. Trametinib already carries FDA approval in BRAF V600E-mutated biliary tract cancer, establishing regulatory precedent for MEK inhibition in this tumor type, even though the KRAS-mutated population in GENFIT’s study operates through a distinct driver. The first-in-human Phase I work with GNS561 established the drug’s oral bioavailability and dose-dependent autophagy inhibition in solid tumors; the Phase 1b data now extend that profile into combination use without the toxicity accumulation that usually complicates dual-pathway suppression.
GENFIT is expanding the Phase 1b with additional cohorts at higher dose levels before finalizing the recommended Phase 2 dose, a pragmatic move that adds dataset strength without delaying the Phase 2 start. That transition is still slated for the second half of 2026. The approval landscape for cholangiocarcinoma has been active, with molecularly selected approvals accumulating across distinct genomic subgroups. GNS561 targets a KRAS-mutated population that has not yet attracted a dedicated approved therapy, which shapes both the regulatory opportunity and the design pressure for Phase 2 to include a credible efficacy endpoint beyond disease stabilization.
The single number to track when Phase 2 launches is progression-free survival at 12 weeks. Stable disease at six weeks in a pretreated population is an acceptable Phase 1b signal, but a Phase 2 readout will need durability data to distinguish meaningful disease control from transient stabilization, and that 12-week PFS rate will be the first credible test of whether the autophagy-plus-MAPK strategy translates into durable clinical benefit in this population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
